Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9506583 | 0.91 | — | — | |
| SCHEMBL16575391 | 0.90 | KDM4E (0.32) | KDM4EALDH1A1GAAHPGDTYMP | |
| SCHEMBL24063626 | 0.87 | — | — | |
| SCHEMBL23720718 | 0.87 | ALDH1A1 (0.30) | KDM4EALDH1A1HPGD | |
| SCHEMBL18134993 | 0.85 | TAS1R3 (0.32) | ALDH1A1 | |
| SCHEMBL24063604 | 0.83 | — | — | |
| SCHEMBL24248341 | 0.83 | KDM4E (0.31) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL9785428 | 0.83 | — | — | |
| SCHEMBL20226509 | 0.83 | NOS2 (0.33) | — | |
| SCHEMBL8166647 | 0.83 | ESR1 (0.38) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022083758-A1 | ANTICOAGULANT ARTIFICIAL HEART VALVE MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 吉林启明皓月生物科技有限公司 | 2022-04-28 | — | — | WO | claimed |
| CN-119708503-A | Preparation method of liquid hyperbranched polycarbosilane containing epoxy active groups and application of liquid hyperbranched polycarbosilane in photocuring 3D printing | 上海信斯帝克新材料有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119708503-A | Preparation method of liquid hyperbranched polycarbosilane containing epoxy active groups and application of liquid hyperbranched polycarbosilane in photocuring 3D printing | 上海信斯帝克新材料有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240025901-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-11785845-B2 | Composition | FUJIFILM CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| US-11547354-B2 | Bio-electrode composition, bio-electrode, and method for manufacturing a bio-electrode | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-10 | — | — | US | disclosed |
| EP-4101835-A1 | 18F-SUBSTITUTED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220213104-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220213296-A1 | DISPERSION LIQUID, COMPOSITION, CURED FILM, COLOR FILTER, SOLID-STATE IMAGING ELEMENT, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20080285133-A1 | Antireflection Film, Production Method Thereof, Polarizing Plate Using the Antireflection Film and Image Display Device Using the Antireflection Film or Polarizing Plate | FUJIFILM CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080088925-A1 | Antireflection Film, Polarizing Plate And Image Display Utilizing The Same | FUJIFILM CORPORATION (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080038472-A1 | Production method of laminate, laminate, polarizing plate and image display device | FUJIFILM CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| EP-0495823-B1 | EPOXIDATION OF FLUORINE CONTAINING OLEFINS | DU PONT (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0495823-A1 | EPOXIDATION OF FLUORINE CONTAINING OLEFINS. | DU PONT (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5084583-A | Epoxidation of fluorine containing olefins | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-28 | — | — | US | disclosed |
| WO-1991005778-A1 | EPOXIDATION OF FLUORINE CONTAINING OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | SLC6A2 4493/4885SLC6A4 4570/4885SLC6A3 4604/4885 |
| US-20240025901-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | INF2, NISCH, ITPA | SLC6A2 4533/4885SLC6A4 4731/4885SLC6A3 4574/4885 |
| US-11785845-B2 | Composition | ADH1A, ADH1C, SLC19A2 | SLC6A2 202/4885SLC6A4 469/4885SLC6A3 733/4885 |
| US-11547354-B2 | Bio-electrode composition, bio-electrode, and method for manufacturing a bio-electrode | KCNN1, KCNN2, KCNN3 | SLC6A2 1727/4885SLC6A4 2765/4885SLC6A3 1469/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | SLC6A2 3588/4885SLC6A4 2336/4885SLC6A3 2277/4885 |
| US-20220213104-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | INF2, NISCH, ITPA | SLC6A2 4533/4885SLC6A4 4731/4885SLC6A3 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.